Shanghai, China, November 23, 2020 — Shanghai MicroPort NeuroTech Co., Ltd. (“MicroPort® NeuroTech”) was recently named Shanghai High-tech “Little Giant” Enterprise by the Shanghai Municipal Science and Technology Commission.
The High-tech “Little Giant” Enterprise Program is an initiative introduced by the Shanghai Municipal Science and Technology Commission and Shanghai Municipal Commission of Economic and Informatization. The program aims to nurture technology-based enterprises with domestic and international competitive advantages, thereby further promoting independent innovation by small and medium-size high-tech enterprises and improving their core competitiveness. MicroPort® NeuroTech has been recognized for its innovation, scale and exemplary role based on assessments by the district and municipal authorities on multiple dimensions. This includes its innovation system and mechanisms, investment in scientific research, independent intellectual property rights, economic scale, growth potentials, as well as credit and financing ability.
Demonstrating its commitment to innovation, MicroPort® NeuroTech currently has five high-end innovative products that have been granted registration certificates by China’s National Medical Products Administration (NMPA), and its products are available in more than 1,000 hospitals across China. Among them, the WILLIS® Intracranial Stent Graft System is not only the world’s first stent graft product approved for marketing for intracranial aneurysms, but also China’s first product of the kind that adopts the concept of intracranial parent artery vessel reconstruction. Additionally, the Tubridge® Vascular Reconstruction Device has completed the NMPA special approval procedure for innovative medical devices, making it the first domestically produced blood flow diverting device approved for marketing in China.
The selection of MicroPort® NeuroTech as a High-tech “Little Giant” Enterprise signifies the recognition by the Shanghai Municipal Government on the company’s improved innovation system, independent innovation capability and comprehensive management strength. MicroPort® NeuroTech will continue to embrace scientific and technological innovation, strengthen its core competitiveness, expand domestic and international markets, and commit itself to becoming a “total solution provider for cerebral apoplexy” for the benefit of more patients in the future.
About MicroPort® NeuroTech
MicroPort® NeuroTech, founded on May 2012, is a subsidiary of MicroPort Scientific Corporation, and has long been committed to the development and industrialization of cerebral apoplexy solutions. It has been granted 96 patents and has undertaken a number of scientific research projects at provincial and ministerial levels. The company has received numerous awards, including the State Science and Technology Advancement Award and the Shanghai Science and Technology Advancement Award. It has been recognized as “Shanghai High-tech Company”, “Shanghai Pilot Company in Patent Operations”, “Shanghai Specialized, Sophisticated, Differentiated and Innovative Company”, “Pudong New Area Corporate R&D Organization” and “Pilot Brand Cultivation Enterprise”.